Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Novel transcript, antisense to ADSSL1" (ENSG00000306386) is a human gene that encodes a long non-coding RNA and is transcribed from the DNA strand opposite to the ADSSL1 gene. This lncRNA is classified as an antisense transcript—its sequence is complementary to ADSSL1, which codes for adenylosuccinate synthase-like 1, a muscle-specific enzyme. The biological role, disease associations, and therapeutic relevance of this antisense lncRNA remain undetermined, and there is no evidence it is a therapeutic or disease-related target. All known disease connections relate instead to protein-coding mutations in ADSSL1, and not to this non-coding transcript[1][3][7].
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to ADSSL1 (ENSG00000306386).